Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes

Ahn, Chang Ho; Kim, Eun Ky; Min, Se Hee; Oh, Tae Jung; Cho, Young Min

doi:10.1111/dom.12831

Cited by 10 publications

(14 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrated significant apoB-48 reductions in the level of tAUC, conducted before and after 6-month treatment with a teneligliptin. So far, in patients with type 2 diabetes, significant postprandial apoB-48 reductions in AUC were reported via lipid or dietary loading after 6-week or 12-week treatment with sitagliptin [23,24], and 4-week treatment with gemigliptin [25]. It is difficult to compare these studies by absolute value because the sampling times and contents of the test meals were different.…”

Section: Reproducibility Of the Results Of Other Apob-48 Studiesmentioning

confidence: 99%

“…Among the DPP4 inhibitors examined for effects on blood apoB-48 levels before and after lipid loading or dietary loading in type 2 DM patients, sitagliptin was reported to have effects after a 6-week treatment [23] and 12-week treatment [24]; gemigliptin was reported to have effects after a 4-week treatment [25]. There are no reports on DPP4 inhibitors' long-term effects on apo-B48 and no reports on teneligliptin pre-and post-meal apo-B48.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Teneligliptin on Lipid Profile: A Prospective Study for Comparison of Biomarkers Before and After a Meal

Takahashi¹,

Kobayashi

Tagawa

et al. 2020

J Endocrinol Metab

View full text Add to dashboard Cite

Background: In the treatment of diabetes mellitus, it is important to prevent dyslipidemia, which is one of the complications. However, no study has examined the long-term effects of teneligliptin on the blood parameters of apolipoprotein B (apoB) after a meal in patients with type 2 diabetes. Methods:The effects of teneligliptin on blood glucose and lipids were examined by measurement of biomarkers before and after a meal. We gathered data before and after 6-month treatment in diabetic patients.Results: After treating 31 patients with teneligliptin for 6 months, the blood level of apoB-48, expressed as total area under the curve (tAUC), was significantly decreased. A multiple regression analysis of factors affecting the decreases in apoB-48 tAUC indicated that apoB-48 is more likely to decrease if it is higher at the start of testing, and that the apoB-48 tAUC value is more likely to fall in women than in men.Conclusions: Teneligliptin may be beneficial for the treatment of postprandial hyperlipidemia in diabetic patients.

show abstract

Section: Reproducibility Of the Results Of Other Apob-48 Studiesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Effects of Teneligliptin on Lipid Profile: A Prospective Study for Comparison of Biomarkers Before and After a Meal

Takahashi¹,

Kobayashi

Tagawa

et al. 2020

J Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…The class of DPP-4 inhibitors is known to be potentially associated with a beneficial effect on cholesterol levels [13, 14]. Several clinical trials have also shown that anagliptin consistently decreased serum cholesterol levels, including LDL-C, [4, 15, 16].…”

Section: Discussionmentioning

confidence: 99%

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Chihara

Tanaka

Morimoto

et al. 2019

Cardiovasc Diabetol

View full text Add to dashboard Cite

Background: Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however remains uncertain. Aim and methods:We therefore evaluate the effects of anagliptin on lipid metabolism-related markers compared with those of sitagliptin. The study was a secondary analysis using data obtained from the Randomized Evaluation of Anagliptin versus Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial. This trial in patients with type 2 diabetes at a high risk of cardiovascular events and on statin therapy showed that anagliptin reduced LDL-C levels to a greater extent than sitagliptin. Cholesterol absorption (campesterol and sitosterol) and synthesis (lathosterol) markers were measured at baseline and 52 weeks in the study cohort (n = 353). Results:There was no significant difference in the changes of campesterol or sitosterol between the two treatment groups (p = 0.85 and 0.55, respectively). Lathosterol concentration was increased significantly at 52 weeks with sitagliptin treatment (baseline, 1.2 ± 0.7 μg/mL vs. 52 weeks, 1.4 ± 1.0 μg/mL, p = 0.02), whereas it did not change in the anagliptin group (baseline, 1.3 ± 0.8 μg/mL vs. 52 weeks, 1.3 ± 0.7 μg/mL, p = 0.99). The difference in absolute change between the two groups showed a borderline significance (p = 0.06). Conclusion:These findings suggest that anagliptin reduces LDL-C level by suppressing excess cholesterol synthesis, even in combination with statin therapy.Trial registration ClinicalTrials.gov number NCT02330406. https ://clini caltr ials.gov/ct2/show/NCT02 33040 6; registered January 5, 2015.

show abstract

“…Fasting serum ApoB48 levels were significantly lower with gemigliptin than with placebo (p= 0.020). However, the plasma ApoB100 levels showed no significant difference (p= 0.734) (49). Study to evaluate cardiovascular outcomes of T2DM patientstreated with gemigliptin is still ongoing.…”

Section: ) Gemigliptinmentioning

confidence: 94%

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Side Effects

Rizal

Suharjono²

2021

PJI

View full text Add to dashboard Cite

Aim: WHO projects that diabetes will be the seventh leading cause of death in 2030. One of the macrovascular of diabetes is cardiovascular (CV) diseases, reported incidence of heart failure in diabetic patients is twice greater than control subjects and intensive use of antidiabetic drugs in diabetic patients increase CV mortality. This review will discusses the effect of DPP4 inhibitors (DPP-4i) on CV outcomes. Data sources: PubMed 32 journals, Google Scholar 17 journals, BioMed Central 5 journals and others 1 journal Method: A systemic search of all English-language articles up to 2020 was conducted using the following terms: dipeptidyl peptidase-4 inhibitors, sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, gemigliptin, anagliptin, teneligliptin, alogliptin, trelagliptin, omarigliptin, cardiovascular, and mechanism on cardiovascular diseases. Results: Positive effect on CV of DPP-4i mediated by activate PI3K, CAMP, eNOS and PKA, and negative effect because their effects in modulate SP, peptide YY, and neuropeptide Y. CV outcomes of DPP-4i versus placebo are variated for MACEs, which are reported on sitagliptin HR 0.98, 95% CI 0.89 to 1.08; Vildagliptin RR 0.82, 95% CI 0.61 to 1.11; Saxagliptin HR 1.00, 95% CI, 0.89 to 1.12; Linagliptin HR 0.78, 95% CI, 0.55 to 1.12; Alogliptin HR 0.85, CI 95%, 0.66 to 1.10; and Omarigliptin HR=0.85, CI 95%, 0.66-1.10. Conclusion: Based on the mechanism DPP-4i inhibitors have either cardioprotective actions or poorer outcomes on CV because their activities are connected with the inhibition of various substrates. DPP-4i sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin, and omarigliptin did not significantly increase of MACE (major adverse cardiac events).

show abstract

Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes

Cited by 10 publications

References 18 publications

The Effects of Teneligliptin on Lipid Profile: A Prospective Study for Comparison of Biomarkers Before and After a Meal

The Effects of Teneligliptin on Lipid Profile: A Prospective Study for Comparison of Biomarkers Before and After a Meal

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Side Effects

Contact Info

Product

Resources

About